ClinicalTrials.Veeva

Menu

Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis (EASE)

E

Escient Pharmaceuticals

Status and phase

Active, not recruiting
Phase 2

Conditions

Atopic Dermatitis

Treatments

Drug: Placebo
Drug: Oral EP262

Study type

Interventional

Funder types

Industry

Identifiers

NCT06144424
EP-262-202

Details and patient eligibility

About

This Phase 2a trial will evaluate the effects of EP262 in subjects with atopic dermatitis

Enrollment

30 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Clinically confirmed diagnosis of active atopic dermatitis for at least 1 year
  • BSA of 3% to 20% and a vIGA-AD score of ≥3

Exclusion criteria

  • Other active skin diseases associated with chronic pruritus
  • Clinically infected atopic dermatitis that requires antibiotic therapy
  • Use of specific treatments for atopic dermatitis

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

30 participants in 2 patient groups, including a placebo group

EP262 150 mg
Experimental group
Treatment:
Drug: Oral EP262
Placebo
Placebo Comparator group
Treatment:
Drug: Placebo

Trial contacts and locations

10

Loading...

Central trial contact

Escient Clinical Trials

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems